DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Propoxyphene Napsylate and Acetaminophen (Propoxyphene Napsylate / Acetaminophen) - Summary

 
 



BOX WARNING

WARNINGS

  • Do not prescribe propoxyphene for patients who are suicidal or addiction-prone.
  • Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs and patients who use alcohol in excess.
  • Tell your patients not to exceed the recommended dose and to limit their intake of alcohol.

Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths. Fatalities within the first hour of overdosage are not uncommon. In a survey of deaths due to overdosage conducted in 1975, in approximately 20% of the fatal cases, death occurred within the first hour (5% occurred within 15 minutes). Propoxyphene should not be taken in doses higher than those recommended by the physician. The judicious prescribing of propoxyphene is essential to the safe use of this drug. With patients who are depressed or suicidal, consideration should be given to the use of non-narcotic analgesics. Patients should be cautioned about the concomitant use of propoxyphene products and alcohol because of potentially serious CNS-additive effects of these agents. Because of its added depressant effects, propoxyphene should be prescribed with caution for those patients whose medical condition requires the concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants, or other CNS-depressant drugs. Patients should be advised of the additive depressant effects of these combinations.

Many of the propoxyphene-related deaths have occurred in patients with previous histories of emotional disturbances or suicidal ideation or attempts as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs. Some deaths have occurred as a consequence of the accidental ingestion of excessive quantities of propoxyphene alone or in combination with other drugs. Patients taking propoxyphene should be warned not to exceed the dosage recommended by the physician.

 

SUMMARY

PROPOXYPHENE NAPSYLATE and ACETAMINOPHEN TABLETS, USP

Each tablet of propoxyphene napsylate and acetaminophen tablets, for oral administration, contains 100 mg (176.8 μmol) propoxyphene napsylate and 650 mg (4,300 μmol) acetaminophen.

Propoxyphene is a centrally acting narcotic analgesic agent.

This product is indicated for the relief of mild to moderate pain, either when pain is present alone or when it is accompanied by fever.


See all Propoxyphene Napsylate and Acetaminophen indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Propoxyphene Napsylate and Acetaminophen (Propoxyphene / Acetaminophen)

More resilient people tend to have a higher pain tolerance
Source: Anxiety / Stress News From Medical News Today [2014.09.13]
Resilience, a person's ability to overcome adverse circumstances, is the main quality associated with pain tolerance among patients and their adjustment to chronic pain.

Avoiding Pain Management Prosecutions
Source: Medscape NeurologyHeadlines [2014.09.12]
The key to staying out of court, says an attorney with years of experience in the field, is keeping up-to-date documentation.
Medscape Medical News

International Conference and Exhibition on Pain Medicine, June 08-10, 2015, Chicago
Source: Conferences News From Medical News Today [2014.09.12]
OMICS Group is pleased to invite you to participate in the International Conference and Exhibition on Pain Medicine during June 08-10, 2015 at Chicago, USA.

Groundbreaking study reveals best positions for sex for men who have back pain
Source: Sexual Health / STDs News From Medical News Today [2014.09.12]
Contrary to popular belief, spooning is not always the best sex position for those with a bad back, according to new research from the University of Waterloo.

OncoBriefs: New Myeloma Standard? Robotics and Pain (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2014.09.12]
(MedPage Today) -- Patients with newly diagnosed multiple myeloma lived longer and had significantly slower disease progression with a new two-drug regimen than with a long-time, standard three-drug regimen, a randomized trial showed.

more news >>

Published Studies Related to Propoxyphene Napsylate and Acetaminophen (Propoxyphene / Acetaminophen)

Analgesic efficacy of tramadol/acetaminophen and propoxyphene/acetaminophen for relief of postoperative wound pain. [2012]
Depain-X in acute postoperative pain... CONCLUSION: Among patients with mild to moderate postoperative wound pain,

Propoxyphene and pain management in the elderly. [2009.11]
Pain is frequently reported and often undertreated in the elderly population.Therefore, it is very important to consider alternatives to propoxyphene such as APAP, nonsteroidal anti-inflammatory drugs (rare use due to adverse effects) and other opioids, when managing elderly patients with pain.

more studies >>

Clinical Trials Related to Propoxyphene Napsylate and Acetaminophen (Propoxyphene / Acetaminophen)

Multiple-Ascending-Dose Study to Evaluate the Safety of Propoxyphene Napsylate In Healthy Adult Subjects [Recruiting]

Lumbar Stenosis Outcomes Research II [Recruiting]
The primary objective of the proposed pilot study is to determine the efficacy of oxymorphone hydrochloride and propoxyphene/acetaminophen combination in prolonging the time to onset of pain and reducing the severity of pain associated with walking in patients with neurogenic intermittent claudication. The secondary objective is to examine the functional benefit of oxymorphone hydrochloride and propoxyphene/acetaminophen combination with respect to improvement in duration and distance of walking tolerance.

The proposed study will also provide the foundation for a treadmill-based methodology for assessing the analgesic efficacy of drugs for low back pain provoked by standing and walking associated with lumbar spinal stenosis.

Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain [Active, not recruiting]
RATIONALE: Oxycodone helps lessen pain caused by cancer and may improve quality of life. It is not yet known whether oxycodone works better and is more cost effective than standard therapy in treating patients with cancer pain.

PURPOSE: This randomized phase IV trial is studying oxycodone to see how well it works compared with standard pain therapy in treating patients with cancer pain and if it is more cost effective than standard pain therapy.

An Effectiveness and Safety Study of Two Doses of Acetaminophen Extended Release Caplets in the Treatment of Osteoarthritis of the Hip or Knee [Completed]
The purpose of this study is to determine the safety and effectiveness of 650 mg and 1300 mg acetaminophen extended release given three times a day for the relief of signs and symptoms of osteoarthritis of the hip or knee for a period of 12 weeks.

Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression [Terminated]
Objectives of the study:

Primary: Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered once daily (QD) for 24 months in slowing disease progression as assessed radiographically in subjects with osteoarthritis (OA) of the hipSecondary: Assess the ability of a continuous treatment of celecoxib 200 mg versus placebo administered QD for 24 months in treating disease signs and symptoms in subjects with OA of the hip. Evaluate the ability of a continuous 24-month intake of celecoxib 200 mg QD versus placebo to reduce number of subjects eligible for hip replacement according to the investigator. Evaluate the tolerability and safety of a continuous 24-month intake of celecoxib 200 mg QD versus placebo in subjects with OA of the hip.

more trials >>

Reports of Suspected Propoxyphene Napsylate and Acetaminophen (Propoxyphene / Acetaminophen) Side Effects

Myocardial Infarction (9)Atrial Fibrillation (8)Palpitations (5)Arrhythmia (4)Blood Pressure Inadequately Controlled (3)Transient Ischaemic Attack (3)Blindness (3)Cardiac Arrest (3)Sudden Death (2)Disorientation (2)more >>


Page last updated: 2014-09-13

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014